Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ATEC vs UFPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UFPT Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

UFPT Overall Winner 6-Pillar Tally: ATEC 3 – 3 UFPT Matrix Metrics: ATEC 4 – 6 UFPT

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Alphatec Holdings, Inc. (ATEC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ATEC carries a Unified Composite Score of 62.5/100 (BUY) at $6.78 (12.2x Forward P/E, -3.0% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin).

  • Composite vs. Pillar Nuance: While ATEC currently prints a higher short-term Unified Composite Score (62.5/100 BUY vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (15.4% vs. -3.0% operating margin) and revenue trajectory (+11.6% vs. +12.6% YoY).
  • Technical & Structure Timing Caution: ATEC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATEC vs UFPT
ATEC NASDAQ
Alphatec Holdings, Inc.
Surgical & Medical Instruments & Apparatus
$6.78
-4.1% 1D
Market Cap $1.1B
TTM Revenue $840M
Forward P/E 12.2x
Beta / 30D Vol 1.35β · 149% Vol
Unified Composite Score
62.5 / 100 BUY
Tech 53.0 Fund 59.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 33
RSI-14: 32.5 · SMA20: $8.84 · SMA50: $9.70
UFPT NASDAQ Head-to-Head Winner
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17

6-Pillar Scorecard Institutional Category Breakdown (ATEC 3 – 3 UFPT)

Columns: Metric · ATEC · UFPT
1. Valuation Multiples ATEC
Forward P/E 12.2x 24.7x
Trailing P/E 13.0x 31.2x
PEG Ratio 0.48x 3.80x
EV / Revenue 1.9x 3.6x
2. Growth & Scale ATEC
Revenue Growth (YoY) +12.6% +11.6%
Earnings Growth (YoY) +0.0% +25.1%
TTM Revenue (USD) $840M $650M
Market Cap $1.1B $2.4B
3. Profitability & Quality UFPT
Gross Margin 71.3% 28.9%
Operating Margin -3.0% 15.4%
Net Profit Margin -10.3% 11.8%
Return on Equity (ROE) -308.1% 17.2%
4. Balance Sheet & Cash Flow UFPT
Cash Generation (TTM) -$10M $120M EBITDA
Cash Flow Margin -1.2% 18.5% EBITDA Mgn
Net Cash / Leverage $514M Net Debt $62.70 Book/Sh · 17.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning UFPT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 67.6% (10th %ile) 42.3% (3rd %ile)
Put/Call OI Skew 0.56x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat ATEC
OpEx & R&D Intensity 74.3% of Rev ($624M) 13.5% of Rev ($88M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATEC (4) vs UFPT (6)
Institutional Metric ATEC UFPT Criterion Row Edge
Market Capitalization
Scale
$1.1B $2.4B Larger Scale UFPT
Trailing P/E Ratio
Valuation
13.0x 31.2x Lower Multiple ATEC
Forward P/E Ratio
Valuation
12.2x 24.7x Lower Multiple ATEC
Revenue Growth (YoY)
Growth
+12.6% +11.6% Higher Growth ATEC
Operating Margin (TTM)
Profitability
-3.0% 15.4% Higher Margin UFPT
Net Profit Margin
Profitability
-10.3% 11.8% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
-308.1% 17.2% Higher ROE UFPT
52-Week Range Position
Momentum
0% ($7–$23) 74% ($174–$342) Stronger Trend UFPT
Beta / 30D Volatility
Risk Regime
1.35β · 149% Vol 1.64β · 77% Vol Lower Realized Risk UFPT
Unified Institutional Score
Composite Signal
62.5 / 100 (BUY) 42.6 / 100 (HOLD) Higher Composite ATEC
Trailing 12M Revenue (USD)
Operating Scale
$840M $650M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.3% 28.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.48x PEG · 1.9x EV/Rev 3.80x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M ($514M Net Debt) $120M EBITDA ($62.70 Book/Sh · 17.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UFPT +37.54 pp
ATEC: -35.18% · UFPT: +2.36%
3M Horizon UFPT +23.94 pp
ATEC: -28.86% · UFPT: -4.92%
6M Horizon UFPT +53.63 pp
ATEC: -16.19% · UFPT: +37.44%
1Y Horizon UFPT +93.86 pp
ATEC: -66.44% · UFPT: +27.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATEC vs UFPT. Trailing 12-month operating profitability (ATEC -3.0% vs UFPT 15.4%) and valuation multiples (ATEC 12.2x vs UFPT 24.7x Forward P/E) are benchmarked directly in Pillar 4 below.

ATEC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$840M
Gross Margin71.3%
Op. Margin-3.0%
ROE / Fwd P/E-308.1% · 12.2x
UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATEC BREAKDOWN
73d in phase · OBV DISTRIBUTION
Current IV 67.6%
IV Percentile 10th %ile
Put/Call OI Skew 0.56x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ATEC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATEC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and -3.0% operating margin.
OpEx & R&D Reinvestment 74.3% of Rev ($624M)
90D Engineering Disclosures 0 Published
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published

Investor FAQ ATEC vs UFPT Key Questions & Quantitative Answers

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Alphatec Holdings, Inc. (ATEC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ATEC carries a Unified Composite Score of 62.5/100 (BUY) at $6.78 (12.2x Forward P/E, -3.0% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin). Composite vs. Pillar Nuance: While ATEC currently prints a higher short-term Unified Composite Score (62.5/100 BUY vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (15.4% vs. -3.0% operating margin) and revenue trajectory (+11.6% vs. +12.6% YoY). Technical & Structure Timing Caution: ATEC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATEC leads the Growth & Scale pillar: ATEC posts +12.6% YoY revenue growth and +0.0% YoY earnings growth on $840M TTM revenue (71.3% gross margin, -3.0% operating margin), compared with UFPT at +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin). On trailing 12-month operating scale, ATEC generates $840M in USD-normalized revenue versus $650M for UFPT. In operating R&D and SG&A reinvestment, ATEC deploys 74.3% of Rev ($624M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($88M) (0 disclosures) for UFPT.

ATEC screens cheaper on headline valuation multiples. ATEC trades at 12.2x Forward P/E, 13.0x Trailing P/E, 0.48x PEG, and 1.9x EV/Revenue (-1.2% FCF margin), whereas UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATEC (-308.1% ROE) versus UFPT (17.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ATEC carries 67.6% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.56x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.35β · 149% Vol realized risk). By comparison, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.